Advaxis, Inc. (ADXS) Analysts See $-0.41 EPS

May 17, 2018 - By Paula Hilliard

Advaxis, Inc. (NASDAQ:ADXS) LogoInvestors sentiment decreased to 1.12 in 2017 Q4. Its down 0.11, from 1.23 in 2017Q3. It is negative, as 17 investors sold Advaxis, Inc. shares while 17 reduced holdings. 16 funds opened positions while 22 raised stakes. 15.17 million shares or 10.45% less from 16.94 million shares in 2017Q3 were reported.
Voya Invest Management Ltd reported 0% stake. State Street Corporation accumulated 646,922 shares. Jane Street Group Limited Liability holds 11,428 shares. Morgan Stanley invested in 0% or 178,381 shares. 57,100 are owned by Price T Rowe Assocs Md. Parametric Port Assoc Ltd holds 17,431 shares. State Board Of Administration Of Florida Retirement Sys holds 0% or 20,505 shares. California State Teachers Retirement Sys holds 58,649 shares. Jpmorgan Chase has 0% invested in Advaxis, Inc. (NASDAQ:ADXS). Prelude Cap Mngmt Limited Liability, a New York-based fund reported 553 shares. Ny State Common Retirement Fund accumulated 34,200 shares. Aqr Mgmt Ltd, a Connecticut-based fund reported 86,208 shares. Millennium Mngmt Limited Liability holds 30,583 shares. Schwab Charles Management reported 0% in Advaxis, Inc. (NASDAQ:ADXS). Goldman Sachs Grp Inc, New York-based fund reported 10,441 shares.

Since December 29, 2017, it had 0 buys, and 3 selling transactions for $20,259 activity. Shares for $94 were sold by LOMBARDO ANTHONY A on Friday, February 2. On Thursday, March 29 PETIT ROBERT sold $3,553 worth of Advaxis, Inc. (NASDAQ:ADXS) or 2,193 shares.

Analysts expect Advaxis, Inc. (NASDAQ:ADXS) to report $-0.41 EPS on June, 5.They anticipate $0.10 EPS change or 19.61 % from last quarter’s $-0.51 EPS. After having $-0.49 EPS previously, Advaxis, Inc.’s analysts see -16.33 % EPS growth. The stock decreased 4.01% or $0.075 during the last trading session, reaching $1.795. About 608,209 shares traded. Advaxis, Inc. (NASDAQ:ADXS) has declined 77.70% since May 17, 2017 and is downtrending. It has underperformed by 89.25% the S&P500.

Advaxis, Inc. (NASDAQ:ADXS) Ratings Coverage

Among 2 analysts covering Advaxis (NASDAQ:ADXS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Advaxis had 3 analyst reports since December 27, 2017 according to SRatingsIntel. H.C. Wainwright maintained Advaxis, Inc. (NASDAQ:ADXS) rating on Wednesday, March 14. H.C. Wainwright has “Buy” rating and $6 target. Cantor Fitzgerald maintained Advaxis, Inc. (NASDAQ:ADXS) on Tuesday, March 13 with “Overweight” rating. The stock of Advaxis, Inc. (NASDAQ:ADXS) has “Buy” rating given on Wednesday, December 27 by H.C. Wainwright.

Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The company has market cap of $93.90 million. The Company’s lead product Axalimogene filolisbac, an Lm-LLO immunotherapy product candidate, which completed its Phase II study for the treatment of human papilloma virus associated cancers, including cervical, head and neck, and anal cancer. It currently has negative earnings. The firm is also developing ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is in Phase I/II clinical trials designed to target the prostate specific antigen associated with prostate cancer; and ADXS-HER2, an Lm-LLO immunotherapy product candidate that is in Phase Ib clinical trials used for the treatment of human epidermal growth factor receptor 2 expressing cancers, including human and canine osteosarcoma.

More news for Advaxis, Inc. (NASDAQ:ADXS) were recently published by:, which released: “Advaxis (ADXS) Says Presented Preclinical Data Show Potential for ADXS-NEO as Anti-Cancer Immunotherapy” on May 11, 2018.‘s article titled: “Analysis: Positioning to Benefit within Advaxis, elf Beauty, Heron Therapeutics, PVH, Energy Recovery, and AO Smith …” and published on May 14, 2018 is yet another important article.

Advaxis, Inc. (NASDAQ:ADXS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: